KITLG and melanoma: Loss of either CUL3, FBXL6, or RBX1 expression conferred a growth advantage in the presence of vemurafenib, indicating that an unimpaired SCF complex is critical for vemurafenib sensitivity in melanoma (Shalem et al., 2014; Kim et al., 2015).